ACADIA Pharmaceuticals Inc. Free Cash Flow Margin

Free Cash Flow Margin of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow Margin growth rates and interactive chart. Free cash flow margin or Free cash flow-to-sales is a performance ratio that measures operating cash flows after deduction of capital expenditures (free cash flow) relative to sales. Free cash flows (FCF) is an important metric in assessing a company's financial condition and determining its intrinsic valuation. FCF/sales is tracked over time and can be compared to a company's historical record or to peers. Free cash flow is useful because it takes out non-cash items out of earnings and only looks at the underlying operating cash coming in and out of a business minus the necessary capital expenditures.


Highlights and Quick Summary

  • Annual Free Cash Flow Margin for 2020 was -32.14% (a -27.22% decrease from previous year)
  • Annual Free Cash Flow Margin for 2019 was -44.16% (a -41.72% decrease from previous year)
  • Annual Free Cash Flow Margin for 2018 was -75.77% (a -56.7% decrease from previous year)
  • Twelve month Free Cash Flow Margin ending December 30, 2020 was -32.14% (a -5.91% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow Margin decreased by -13.72% year-over-year
Trailing Free Cash Flow Margin for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
-32.14% -34.16% -34.93% -37.25%
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow Margin of ACADIA Pharmaceuticals Inc.

Most recent Free Cash Flow Marginof ACAD including historical data for past 10 years.

Interactive Chart of Free Cash Flow Margin of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Free Cash Flow Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -32.14%
2019 -44.16%
2018 -75.77%
2017 -174.99%
2016 -1257.37%
2015 -203173.77%
2014 -55511.67%
2013 -2827.51%
2012 -435.72%
2011 -962.75%
2010 -25.1%

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.